Study record

Mitochondrial-derived peptides: New markers for cardiometabolic dysfunction

Rochette L, Rigal E, Dogon G et al. · Arch Cardiovasc Dis · 2022

ReviewEndogenous MOTS-c measuredEvidence tier R

What this study reported

Reviewed humanin, MOTS-c and small humanin-like peptides as circulating markers that may reflect mitochondrial function in cardiometabolic disease. Described their reported antioxidant, anti-inflammatory and anti-apoptotic actions and discussed their proposed use as biomarkers.

Limitations

Narrative review without systematic search; biomarker claims rest on small cross-sectional human studies and assay methods differ between them.

Study record

Annotated fields for this study
Study modelReview
Substance studiedEndogenous MOTS-c measuredNaturally occurring MOTS-c was measured; nothing was given.
SpeciesNot reported
System studiedNarrative review of circulating mitochondrial-derived peptides as cardiometabolic biomarkers
PopulationNot reported
DesignNarrative review
Sample size as reportedNot reported
Control groupNot reported
Route (data field only)Not reported
Endpoints measuredcirculating MDP concentrations; oxidative stress; inflammation; apoptosis
Pathways measuredOxidative stress · Inflammation · Apoptosis · Nuclear translocation
Research areasCardiovascular · Metabolic
Evidence tierR — Review (context, not evidence)
Publication typesJournal Article, Review

Appraisal

Each dimension is recorded separately and never combined into a single score. A study can be well controlled and still tell you little about people.

Relevance to MOTS-c
Indirect
Model applicability
n/a
Sample size
n/a
Controls
n/a
Outcome validity
n/a
Support for its own conclusion
Moderate

Provenance

  • Bibliographic fields retrieved from PubMed E-utilities efetch (title, journal, date, authors, DOI) on 2026-11-11.
  • Annotated from the published abstract.
  • Editorial review: approved (2026-11-11).
  • Classification follows the site methodology; the record describes the study, not what MOTS-c does in people.